Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety.

Next Previous
Trial Profile

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clopidogrel (Primary)
  • Indications Acute coronary syndromes; Coronary arteriosclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms GRAVITAS
  • Sponsors Accumetrics

Most Recent Events

  • 15 Jun 2011 Actual end date changed from Aug 2010 to Oct 2010 as reported by ClinicalTrials..gov. (Parent trial, NCT00645918)
  • 15 Mar 2011 Results will be published in the Journal of the American Medical Association, according to an Accumetrics media release.
  • 13 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top